Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,959 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors.
Saito T, Kurose K, Kojima T, Funakoshi T, Sato E, Nishikawa H, Nakajima J, Seto Y, Kakimi K, Iida S, Doki Y, Oka M, Ueda R, Wada H. Saito T, et al. Among authors: sato e. Nagoya J Med Sci. 2021 Nov;83(4):827-840. doi: 10.18999/nagjms.83.4.827. Nagoya J Med Sci. 2021. PMID: 34916725 Free PMC article. Clinical Trial.
A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, Doki Y, Nakajima J, Seto Y, Yamatsuji T, Naomoto Y, Shiraishi K, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Oka M, Pan L, Hoffman EW, Old LJ, Nakayama E. Kakimi K, et al. Among authors: sato e. Int J Cancer. 2011 Dec 15;129(12):2836-46. doi: 10.1002/ijc.25955. Epub 2011 Mar 29. Int J Cancer. 2011. PMID: 21448901 Clinical Trial.
Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, Udono H, Seto Y, Yamada K, Nishikawa H, Pan L, Venhaus R, Oka M, Doki Y, Nakayama E. Wada H, et al. Among authors: sato e. J Immunother. 2014 Feb-Mar;37(2):84-92. doi: 10.1097/CJI.0000000000000017. J Immunother. 2014. PMID: 24509171 Clinical Trial.
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, Ezoe S, Kanakura Y, Sato E, Fukumori Y, Karbach J, Jäger E, Sakaguchi S. Sugiyama D, et al. Among authors: sato e. Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17945-50. doi: 10.1073/pnas.1316796110. Epub 2013 Oct 14. Proc Natl Acad Sci U S A. 2013. PMID: 24127572 Free PMC article.
NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC.
Takeoka T, Nagase H, Kurose K, Ohue Y, Yamasaki M, Takiguchi S, Sato E, Isobe M, Kanazawa T, Matsumoto M, Iwahori K, Kawashima A, Morimoto-Okazawa A, Nishikawa H, Oka M, Pan L, Venhaus R, Nakayama E, Mori M, Doki Y, Wada H. Takeoka T, et al. Among authors: sato e. J Immunother. 2017 May;40(4):140-147. doi: 10.1097/CJI.0000000000000162. J Immunother. 2017. PMID: 28338507
Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer.
Yamamoto K, Makino T, Sato E, Noma T, Urakawa S, Takeoka T, Yamashita K, Saito T, Tanaka K, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Mori M, Doki Y, Wada H. Yamamoto K, et al. Among authors: sato e. Cancer Sci. 2020 Apr;111(4):1103-1112. doi: 10.1111/cas.14328. Epub 2020 Feb 18. Cancer Sci. 2020. PMID: 31981293 Free PMC article.
Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer.
Fujiwara S, Wada H, Miyata H, Kawada J, Kawabata R, Nishikawa H, Gnjatic S, Sedrak C, Sato E, Nakamura Y, Sakakibara M, Kanto T, Shimosegawa E, Hatazawa J, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Nakayama E, Mori M, Doki Y. Fujiwara S, et al. Among authors: sato e. J Immunother. 2012 Jul;35(6):513-21. doi: 10.1097/CJI.0b013e3182619cb4. J Immunother. 2012. PMID: 22735809 Clinical Trial.
1,959 results